EPO Upholds Stay on Mirrx Patent Proceedings as Santaris Pushes Ahead with HCV Rx
August 26, 2010
EPO Upholds Stay on Mirrx Patent Proceedings as Santaris Pushes Ahead with HCV Rx
Earlier this year, Santaris sued Mirrx for allegedly using illegally obtained trade secrets to file European patent applications on a miRNA-inhibiting technology with therapeutic applications. The legal battle has raised questions about Santaris' HCV drug miravirsen.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- EPO Rejects Mirrx Bid to Reinstate Patent Proceedings Ahead of Ruling on Suit with Santaris
July 21, 2011 / Gene Silencing News - EPO to Hear Mirrx Request for Resumption of Patent Proceedings Covering miRNA Rx Technology
January 20, 2011 / Gene Silencing News - Santaris Sues Mirrx Founder Over Blockmir Technology
May 6, 2010 / Gene Silencing News - UNC Researchers Report New Details on Role of miR-122 in HCV
December 20, 2012 / Gene Silencing News - People in the News: Soren Tulstrup, Henrik Stage
May 31, 2012 / Gene Silencing News